TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06240520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 MG Oral Capsule
Description: Panobinostat 20mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 MG Oral Capsule
Description: Panobinostat 20mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 MG Oral Capsule
Description: Panobinostat 20mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 200mg Oral Tablet
Description: Pyrimethamine 200mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 200mg Oral Tablet
Description: Pyrimethamine 200mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 200mg Oral Tablet
Description: Pyrimethamine 200mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 MG Oral Capsule
Description: Lenalidomide 25mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 MG Oral Capsule
Description: Lenalidomide 25mg will be administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 MG Oral Capsule
Description: Lenalidomide 25mg will be administered once orally
Study: NCT06390046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Comparing videao laryngospy with traditional laryngoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA versus Inhalation
Description: comparing TIVA with genera anesthesia with inhalation agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA versus Inhalation
Description: comparing TIVA with genera anesthesia with inhalation agent
Study: NCT04980625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
Study: NCT04644198

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma Infusion
Description: 250 mls of convalescent plasma on day 1 \& 2.
Study: NCT06491225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTE001 injection
Description: GTE-001 injection to treat Advanced lung adenocarcinoma
Study: NCT06263244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Monoclonal antibody targeting IL-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04957680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT
Description: computer-based treatment program for depressed adolescents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCBT
Description: computer-based treatment program for depressed adolescents
Study: NCT05978349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro
Description: Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Study: NCT04880772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: exercise \& multivitamin (nutritional/dietary advice)
Study: NCT05489744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Afuresertib
Description: Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
Study: NCT05312684

Intervention type: PROCEDURE
Intervention: cardiac surgery
Description: cardiovascular surgery including valve repair/replacement or CABG or combined procedures
Study: NCT05096546

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied for the observational study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied for the observational study.
Study: NCT06511544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
Study: NCT06513390

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exoskeleton of default mode
Description: Default mode: A standard control system offering a conventional assistive function of Exo-H3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoskeleton of default mode
Description: Default mode: A standard control system offering a conventional assistive function of Exo-H3.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exoskeleton of Intelligent mode
Description: Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoskeleton of Intelligent mode
Description: Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
Study: NCT04565912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sage extract mouthwash
Description: Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorohexidine based mouthwash
Description: Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
Study: NCT04803175

Intervention type: DRUG
Intervention: Sacubitril-Valsartan
Description: Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.

Intervention type: DRUG
Intervention: Valsartan
Description: Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
Study: NCT05079347

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV rapid test
Description: Using a rapid test to assess a patient's HIV status
Study: NCT05096637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PreventiPlaque App
Description: PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
Study: NCT06207552

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BBM-F101 injection
Description: The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
Study: NCT05765058

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group A
Description: Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B
Description: Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C
Description: Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group D
Description: Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
Study: NCT05481983

Intervention type: OTHER
Group type: OTHER
Intervention: Walk exercise
Description: The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one clinical exercise training
Description: One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
Study: NCT04430257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV and PrEP education
Description: Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving and planning
Description: Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP information
Description: A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PrEP information
Description: A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referrals
Description: Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
Study: NCT05889468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
Study: NCT05359679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value Champion Training Program
Description: Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Usual clinical care - no value champion present at this clinical setting
Study: NCT04075539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based cycling program
Description: Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~* 1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~* a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~* 3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: A prescription of 6 sessions of outpatient physiotherapy
Study: NCT05544071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Compare active coil with sham coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Compare active coil with sham coil.
Study: NCT04767295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Albumin Paclitaxel, Carboplatin
Description: Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
Study: NCT04460040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake.
Study: NCT05469841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic pain assessment
Description: Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
Study: NCT05783518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: Intraoperative anesthesia maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: Intraoperative anesthesia maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Intraoperative anesthesia maintenance
Study: NCT06016257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of VirtuaCare™ for home program
Description: Use of VirtuaCare™ system for the Home Program.
Study: NCT06011980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Inhibitor
Description: growth inhibitors for 250-500μg/h, ivgtt. for 5 days
Study: NCT05546710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry treatment
Description: The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
Study: NCT04797455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-Based Parenting Intervention
Description: The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
Study: NCT05005273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06178757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EOIB
Description: As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
Study: NCT05985590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinyl Estradiol
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinyl Estradiol
Description: Specified dose on specified days
Study: NCT04530149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
Study: NCT05680649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
Study: NCT05641506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangzheng Xiaoji
Description: Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.
Study: NCT06425263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose tissue fragmented
Description: harvested from the case form buccal pad of fat

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adipose tissue fragmented
Description: harvested from the case form buccal pad of fat
Study: NCT05783518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Intraoperative anesthesia maintenance
Study: NCT04750486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential compression devices
Description: Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
Study: NCT06196996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The method of islet transplantation is through percutaneous transhepatic portal vein puncture.
Description: The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.